| Literature DB >> 24606836 |
Amélie Anota1, Caroline Bascoul-Mollevi, Thierry Conroy, Francis Guillemin, Michel Velten, Damien Jolly, Mariette Mercier, Sylvain Causeret, Jean Cuisenier, Olivier Graesslin, Zeinab Hamidou, Franck Bonnetain.
Abstract
BACKGROUND: The occurrence of response shift (RS) in longitudinal health-related quality of life (HRQoL) studies, reflecting patient adaptation to disease, has already been demonstrated. Several methods have been developed to detect the three different types of response shift (RS), i.e. recalibration RS, 2) reprioritization RS, and 3) reconceptualization RS. We investigated two complementary methods that characterize the occurrence of RS: factor analysis, comprising Principal Component Analysis (PCA) and Multiple Correspondence Analysis (MCA), and a method of Item Response Theory (IRT).Entities:
Mesh:
Year: 2014 PMID: 24606836 PMCID: PMC4016038 DOI: 10.1186/1477-7525-12-32
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Baseline patient characteristics
| | | |
| Dijon | 271 | 71.1 |
| Nancy | 74 | 19.4 |
| Reims | 18 | 4.7 |
| Strasbourg | 18 | 4.7 |
| | | |
| Confirmed primary breast cancer | 242 | 63.5 |
| Suspicion of primary breast cancer | 138 | 36.2 |
| Unknown | 1 | 0.3 |
| | | |
| Confirmed | 340 | 89.2 |
| Not confirmed | 38 | 10.0 |
| Unknown | 3 | 0.8 |
| | | |
| Axillary LND | 138 | 36.2 |
| Sentinel lymph node biopsy | 131 | 34.4 |
| ALND + SLNB | 32 | 8.4 |
| No LND | 75 | 19.7 |
| Unknown | 5 | 1.3 |
| | | |
| Mastectmoy | 124 | 32.6 |
| No mastectomy | 241 | 63.3 |
| Unknown | 16 | 4.2 |
| | | |
| Yes | 155 | 40.7 |
| No | 218 | 57.2 |
| Unknown | 8 | 2.1 |
| | | |
| Yes | 254 | 66.7 |
| No | 119 | 31.2 |
| Unknown | 8 | 2.1 |
| | | |
| Yes | 170 | 44.6 |
| No | 203 | 53.3 |
| Unknown | 8 | 2.1 |
| | | |
| Arm 1: then-test/post-test | 192 | 50.4 |
| Arm 2: post-test/then-test | 189 | 49.6 |
Description of the EORTC QLQ-C30 and BR23 questionnaires received at each measurement time
| Baseline | | 359 (94.2%) | | 357 (93.7%) |
| After surgery | 347 (91.1%) | 347 (91.1%) | 347 (91.1%) | 346 (90.8%) |
| 3 months | 339 (90.0%) | 342 (89.8%) | 355 (87.9%) | 340 (89.2%) |
| 6 months | 314 (82.4%) | 322 (84.5%) | 313 (82.1%) | 322 (84.5%) |
Recalibration component of response shift effect assessed with the then-test method at each measurement time
| | | | | | | | | | | | | | | | | |
| Global Health Status | 310 | 68.66 (20.52) | 280 | -0.80 (16.67) | 0.600 | -0.04 | 275 | 300 | 60.02 (20.19) | 266 | 0.91 (21.30) | 0.48 | 0.05 | |||
| Physical functioning | 313 | 90.01 (15.50) | 283 | -0.50 (10.78) | 0.987 | -0.03 | 280 | -1.59 (13.26) | 0.053 | -0.11 | 301 | 81.31 (16.76) | 273 | |||
| Role functioning | 309 | 89.28 (20.38) | 281 | -1.90 (18.70) | 0.182 | -0.09 | 282 | 300 | 74.06 (30.16) | 269 | ||||||
| Emotional functioning | 308 | 64.86 (26.20) | 279 | 280 | 300 | 72.80 (22.54) | 270 | -2.85 (24.55) | 0.054 | -0.11 | ||||||
| Cognitive functioning | 313 | 83.23 (20.76) | 280 | 2.80 (14.97) | 0.027 | 0.13 | 281 | 2.37 (18.27) | 0.041 | 0.11 | 301 | 82.84 (21.11) | 239 | 4.03 (20.80) | 0.004 | 0.17 |
| Social functioning | 307 | 90.34 (18.88) | 264 | -0.51 (16.18) | 0.644 | -0.03 | 276 | 298 | 81.37 (25.42) | 266 | ||||||
| Fatigue | 310 | 22.89 (22.92) | 278 | -1.48 (18.22) | 0.039 | -0.06 | 279 | 1.75 (20.92) | 0.228 | 0.08 | 300 | 32.82 (24.08) | 270 | |||
| Nausea and vomiting | 312 | 3.53 (11.18) | 270 | -0.77 (8.34) | 0.130 | -0.07 | 282 | 1.77 (15.11) | 0.092 | 0.16 | 299 | 3.44 (10.90) | 269 | -3.22 (19.95) | 0.010 | -0.18 |
| Pain | 316 | 12.45 (20.87) | 285 | 0.53 (19.04) | 0.897 | 0.02 | 283 | 3.24 (23.03) | 0.032 | 0.15 | 304 | 25.08 (24.82) | 274 | |||
| Dyspnea | 310 | 11.72 (31.87) | 280 | -2.02 (15.19) | 0.036 | -0.09 | 279 | -1.08 (15.58) | 0.333 | -0.05 | 301 | 12.86 (20.89) | 269 | -3.59 (24.08) | 0.009 | -0.15 |
| Insomnia | 307 | 38.11 (31.87) | 277 | -5.30 (27.14) | 0.003 | -0.17 | 274 | 299 | 36.63 (30.27) | 266 | ||||||
| Appetite loss | 312 | 11.75 (22.46) | 280 | -3.45 520.35 | 0.005 | -0.15 | 280 | -1.19 (23.75) | 0.323 | -0.05 | 299 | 10.20 (20.13) | 267 | -4.62 (25.02) | 0.004 | -0.18 |
| Constipation | 310 | 12.47 (22.80) | 276 | -1.09 (21.15) | 0.520 | -0.05 | 277 | 1.56 (24.93) | 0.284 | 0.07 | 298 | 21.38 (30.87) | 264 | -4.29 (26.61) | 0.006 | -0.16 |
| Diarrhea | 309 | 8.63 (16.48) | 278 | -2.88 (12.66) | <0.001 | -0.17 | 277 | -2.89 (17.25) | 0.010 | -0.17 | 296 | 4.76 (12.30) | 263 | -0.63 (22.07) | 0.483 | -0.04 |
| Financial difficulties | 300 | 4.56 (14.60) | 264 | 0.38 (12.83) | 0.741 | 0.03 | 269 | 0.99 (16.51) | 0.453 | 0.07 | 299 | 5.86 (15.93) | 264 | -2.15 (18.14) | 0.048 | -0.10 |
| | | | | | | | | | | | | | | | | |
| Body image | 295 | 90.04 (17.32) | 262 | -0.76 (11.95) | 0.505 | -0.05 | 257 | 302 | 70.76 (30.77) | 269 | ||||||
| Sexual functioning | 274 | 76.46 (24.01) | 232 | -0.50 (13.82) | 0.207 | -0.02 | 222 | -1.21 (15.92) | 0.206 | -0.05 | 267 | 79.65 (22.06) | 224 | -4.69 (18.52) | 0.002 | -0.21 |
| Sexual enjoyment | 126 | 43.92 (28.79) | 99 | 2.36 (11.91) | 0.124 | 0.09 | 100 | 3.33 (22.97) | 0.284 | 0.12 | 138 | 52.17 (29.31) | 108 | -1.54 (23.41) | 0.548 | -0.06 |
| Future perspective | 295 | 47.46 (30.86) | 261 | 259 | 301 | 54.49 (32.76) | 269 | -0.12 (33.02) | 0.968 | -0.01 | ||||||
| STSE | 308 | 13.29 (15.30) | 280 | -1.71 (9.89) | 0.008 | -0.11 | 271 | 0.73 (13.84) | 0.563 | 0.05 | 301 | 25.13 (20.20) | 271 | |||
| Breast symptoms | 273 | 11.25 (14.92) | 243 | -0.73 (14.39) | 0.152 | -0.05 | 239 | 2.15 (19.76) | 0.379 | 0.14 | 302 | 24.73 (22.97) | 273 | |||
| Arm symptoms | 297 | 8.06 (14.42) | 268 | 1.58 (18.49) | 0.572 | 0.11 | 261 | 2.43 (16.53) | 0.011 | 0.17 | 302 | 16.39 (18.54) | 273 | -2.71 (17.70) | 0.010 | -0.15 |
| Hair loss | 55 | 32.73 (36.57) | 34 | 0.98 (17.38) | 0.749 | 0.03 | 31 | 1.08 (25.07) | 0.506 | 0.03 | 131 | 53.69 (39.78) | 54 | -8.03 (40.92) | 0.173 | -0.21 |
P: Wilcoxon matched test P value.
SD: standard deviation.
Results in bold correspond to clinically and statistically significant results.
Main recalibration profiles highlighted by a multiple correspondence analysis performed on the EORTC QLQ-C30
| Physical functioning | T1 - T2_Ra | 100 | 37% (272) | Q1-Q5 | Q1-Q5 | | | Q1-Q5 |
| (Q1, Q5) | T1 - T3_Rb | 139 | 51% (274) | Q1-Q5 | Q1-Q5 | | | Q1-Q5 |
| | T3 - T4_Rc | 201 | 76% (266) | Q1-Q5 | Q1-Q5 | | | Q1-Q5 |
| Role functioning | T1 - T2_R | 84 | 31% (272) | Q6, Q7 | Q6, Q7 | | | Q6, Q7 |
| (Q6-Q7) | T1 - T3_R | 118 | 43% (274) | Q6, Q7 | Q6, Q7 | Q6, Q7 | Q6, Q7 | |
| | T3 - T4_R | 164 | 63% (261) | Q6, Q7 | Q6, Q7 | | | Q6, Q7 |
| Emotional functioning | T1 - T2_R | 180 | 68% (263) | Q21-Q24 | Q21-Q24 | | | |
| (Q21-Q24) | T1 - T3_R | 208 | 79% (263) | Q21-Q24 | Q21-Q24 | | | |
| | T3 - T4_R | 196 | 77% (255) | Q21-Q24 | Q21-Q24 | | | Q21-Q24 |
| Cognitive functioning | T1 - T2_R | 103 | 39% (266) | Q20, Q25 | | | | |
| (Q20, Q25) | T1 - T3_R | 129 | 48% (268) | Q20, Q25 | Q20, Q25 | Q20, Q25 | Q20, Q25 | Q20, Q25 |
| | T3 - T4_R | 130 | 51% (256) | Q20, Q25 | Q20, Q25 | Q20, Q25 | Q20, Q25 | |
| Social functioning | T1 - T2_R | 75 | 29% (260) | Q26, Q27 | Q26, Q27 | | | Q26, Q27 |
| (Q26, Q27) | T1 - T3_R | 101 | 38% (268) | Q26, Q27 | Q26, Q27 | Q26, Q27 | Q26, Q27 | |
| | T3 - T4_R | 142 | 56% (255) | Q26, Q27 | Q26, Q27 | Q26, Q27 | Q26, Q27 | Q26, Q27 |
| Fatigue | T1 - T2_R | 141 | 54% (259) | Q10, Q12, Q18 | Q10, Q12, Q18 | | | Q10, Q12, Q18 |
| (Q10, Q12, Q18) | T1 - T3_R | 160 | 61% (261) | Q10, Q12, Q18 | Q10, Q12, Q18 | Q12 | Q10, Q12, Q18 | Q10, Q12, Q18 |
| | T3 - T4_R | 183 | 73% (251) | Q10, Q12, Q18 | Q10, Q12, Q18 | | Q10, Q12, Q18 | Q10, Q12, Q18 |
| Nausea and vomiting | T1 - T2_R | 37 | 13% (280) | Q14 | Q14, Q15 | | | Q14, Q15 |
| (Q14, Q15) | T1 - T3_R | 65 | 24% (275) | Q14 | Q14 | | Q14 | |
| | T3 - T4_R | 98 | 37% (265) | Q14 | Q14 | | | |
| Pain | T1 - T2_R | 96 | 36% (267) | Q9 | Q9 | | | Q9, Q19 |
| (Q9, Q19) | T1 - T3_R | 124 | 46% (268) | Q9, Q19 | Q9, Q19 | | | Q9, Q19 |
| | T3 - T4_R | 148 | 58% (253) | Q9, Q19 | Q9, Q19 | | Q9, Q19 | |
| Insomnia | T1 - T2_R | 115 | 42% (277) | Q11 | Q11 | | Q11 | |
| (Q8) | T1 - T3_R | 135 | 49% (274) | Q11 | Q11 | Q11 | Q11 | |
| | T3 - T4_R | 147 | 55% (266) | Q11 | Q11 | Q11 | Q11 | |
| Dyspnea | T1 - T2_R | 50 | 18% (280) | Q8 | Q8 | | Q8 | |
| (Q11) | T1 - T3_R | 55 | 20% (279) | Q8 | Q8 | Q8 | Q8 | |
| | T3 - T4_R | 94 | 35% (269) | Q8 | Q8 | Q8 | Q8 | |
| Appetite loss | T1 - T2_R | 61 | 22% (280) | Q13 | Q13 | | Q13 | |
| (Q13) | T1 - T3_R | 85 | 30% (280) | Q13 | Q13 | | Q13 | |
| | T3 - T4_R | 90 | 34% (267) | Q13 | Q13 | | Q13 | |
| Constipation | T1 - T2_R | 71 | 26% (276) | Q16 | Q16 | Q16 | Q16 | |
| (Q16) | T1 - T3_R | 89 | 32% (277) | Q16 | Q16 | Q16 | Q16 | |
| | T3 - T4_R | 93 | 35% (264) | Q16 | Q16 | Q16 | Q16 | |
| Diarrhea | T1 - T2_R | 39 | 14% (278) | Q17 | Q17 | | | |
| (Q17) | T1 - T3_R | 64 | 23% (277) | Q17 | Q17 | | | |
| | T3 - T4_R | 61 | 24% (263) | Q17 | Q17 | | Q17 | |
| Financial difficulties | T1 - T2_R | 22 | 8% (264) | Q28 | Q28 | | | |
| (Q28) | T1 - T3_R | 33 | 12% (269) | Q28 | Q28 | | Q28 | |
| T3 - T4_R | 47 | 18% (264) | Q28 | Q28 | Q28 |
Only patients with a recalibration of 5-point at least between a pre-test and a then-test measure are incorporated in these analyses. Items with observed recalibration are listed.
aT1 → T2_R: comparison of baseline HRQoL assessment and retrospective measure performed after surgery.
bT1 → T3_R: comparison of baseline HRQoL assessment and retrospective measure performed three months later.
cT3 → T4_R: comparison of HRQoL assessment at three months and retrospective measure performed three months later.
As example, 100 patients presented a significant recalibration of physical functioning among the 272 patients with all the five items of the dimension answered at both measurement time. The graph representing the response categories highlight some recalibration profile:
- patients who had chosen response category 1 at the prospective measurement time for all the 5 items and who had chosen response category 2 to the same items at the retrospective measurement time.
- patients who had chosen response category 2 at the prospective measurement time for all the 5 items and who had chosen response category 1 to the same items at the retrospective measurement time.
- no recalibration profile is highlighted for response categories 3 and 4 and few patients had chosen these categories of response (these response categories are dispersed).
Main recalibration profiles highlighted by multiple correspondence analysis performed on the QLQ-BR23 for patients with recalibration
| Body image | T1-T2_Ra | 68 | 29% (236) | Q9-Q12 | Q9-Q12 | | | Q9, Q10 | Q9-Q12 |
| (Q9-Q12) | T1-T3_Rb | 119 | 50% (238) | Q9-Q12 | Q9-Q12 | | Q9, Q12 | | Q9-Q12 |
| | T3-T4_Rc | 153 | 63% (244) | Q9, Q10 | Q9, Q10 | | | | Q9-Q12 |
| Sexual functioning | T1-T2_R | 55 | 25% (219) | Q14 | | Q14 | | | |
| (Q14, Q15) | T1-T3_R | 71 | 34% (210) | Q14 | | Q14, Q15 | | | |
| | T3-T4_R | 78 | 37% (213) | Q14, Q15 | Q14, Q15 | Q14, Q15 | | | |
| Sexual enjoyment | T1-T2_R | 13 | 13% (99) | Q16 | Q16 | Q16 | Q16 | Q16 | |
| (Q16) | T1-T3_R | 39 | 39% (100) | Q16 | Q16 | Q16 | Q16 | Q16 | |
| | T3-T4_R | 33 | 31% (108) | Q16 | Q16 | Q16 | Q16 | Q16 | |
| Future perspectives | T1-T2_R | 122 | 47% (261) | Q13 | Q13 | Q13 | Q13 | Q13 | |
| (Q13) | T1-T3_R | 135 | 52% (259) | Q13 | Q13 | | Q13 | Q13 | |
| | T3-T4_R | 144 | 54% (269) | Q13 | Q13 | | Q13 | Q13 | |
| Systemic therapy side effects | T1-T2_R | 55 | 26% (209) | | | | | | |
| (Q1-Q4, Q6-Q8) | T1-T3_R | 61 | 32% (190) | | | | | | |
| | T3-T4_R | 77 | 39% (200) | | | | | | |
| Breast symptoms | T1-T2_R | 114 | 51% (223) | Q20-Q23 | Q20-Q23 | | | | Q20-Q23 |
| (Q20-Q23) | T1-T3_R | 135 | 61% (223) | Q20-Q23 | Q20-Q23 | Q20-Q23 | | Q20-Q23 | Q20-Q23 |
| | T3-T4_R | 190 | 74% (258) | Q20-Q23 | Q20-Q23 | Q20-Q23 | | | Q20-Q23 |
| Arm symptoms | T1-T2_R | 97 | 38% (255) | Q17-Q19 | Q17-Q19 | | | | Q17-Q19 |
| (Q17-Q19) | T1-T3_R | 111 | 46% (244) | Q17-Q19 | Q17-Q19 | | | Q17 | Q17-Q19 |
| | T3-T4_R | 156 | 60% (260) | Q17 | Q17-Q19 | | | | Q17-Q19 |
| Hair loss | T1-T2_R | 6 | 18% (34) | Q5 | | Q5 | | Q5 | |
| (Q5) | T1-T3_R | 14 | 45% (31) | Q5 | | Q5 | Q5 | Q5 | |
| T3-T4_R | 24 | 44% (54) | Q5 | Q5 | Q5 | Q5 | |||
Only patients with a recalibration of 5-point at least between a pre-test and a then-test measure are incorporated in these analyses. Items with observed recalibration are listed.
aT1 → T2_R: comparison of baseline HRQoL assessment and retrospective measure performed after surgery.
bT1 → T3_R: comparison of baseline HRQoL assessment and retrospective measure performed three months later.
cT3 → T4_R: comparison of HRQoL assessment at three months and retrospective measure performed three months later.
Figure 1Variable response categories according the first two axes obtained by Multiple Correspondence Analysis between prospective measure of role functioning at baseline and retrospective measure after surgery (N = 84). Questions 6 and 7 of the EORTC QLQ-C30 measure this dimension: Qi_k (or Ri_k) refers to the k-th category of the i-th item of a prospective (or retrospective) questionnaire on the graph. Patients are represented by circles that are proportional to the number of patients with the same coordinates (i.e. who had given the same responses).
Trend τ of item easiness parameter estimated by linear logistic model with relaxed assumptions for each quality of life dimension
| QLQ-C30 | | | | | | | | | | |
| Physical functioning | 1 – 4d | 100 | -0.02 | 0.858 | 139 | 0.27 | 0.004 | 201 | -0.84 | <0.001 |
| Role functioning | 6, 7 | 84 | 0.36e | 0.011 | 118 | 0.71 | <0.001 | 164 | -0.60 | <0.001 |
| Emotional functioning | 21 - 24 | 180 | -0.62 | <0.001 | 208 | -0.65 | <0.001 | 196 | 0.22 | <0.001 |
| Cognitive functioning | 20, 25 | 103 | -1.15 | <0.001 | 129 | -0.29 | 0.020 | 130 | -0.53 | <0.001 |
| Social functioning | 26, 27 | 75 | 0.07 | 0.791 | 101 | 0.66 | <0.001 | 142 | -0.51 | <0.001 |
| Fatigue | 10, 12, 18 | 141 | -0.19 | 0.280 | 160 | 0.23 | 0.019 | 183 | -0.99 | <0.001 |
| Nausea and vomiting | 14, 15 | 37 | -0.60 | 0.022 | 65 | 0.50 | 0.029 | 98 | -0.36 | 0.003 |
| Pain | 9, 19 | 96 | 0.11 | 0.410 | 124 | 0.37 | 0.001 | 148 | -0.54 | <0.001 |
| Dyspnea | 8 | 50 | -0.60 | 0.025 | 55 | -0.30 | 0.248 | 94 | -0.42 | 0.014 |
| Insomnia | 11 | 115 | -0.49 | 0.001 | 135 | -0.49 | <0.001 | 147 | -0.36 | 0.005 |
| Appetite loss | 13 | 61 | -0.59 | 0.004 | 85 | -0.14 | 0.401 | 90 | -0.51 | 0.003 |
| Constipation | 16 | 71 | -0.16 | 0.392 | 89 | 0.17 | 0.295 | 93 | -0.41 | 0.009 |
| Diarrhea | 17 | 39 | -1.34 | <0.001 | 64 | -0.67 | 0.005 | 61 | -0.09 | 0.641 |
| Financial difficulties | 28 | 22 | 0.16 | 0.630 | 33 | 0.25 | 0.322 | 47 | -0.45 | 0.053 |
| QLQ-BR23 | | | | | | | | | | |
| Body image | 9 - 12 | 68 | 0.10 | 0.489 | 119 | 0.83 | <0.001 | 153 | -0.66 | <0.001 |
| Sexual functioning | 14, 15 | 55 | 0.06 | 0.950 | 71 | 0.33 | 0.078 | 78 | 0.77 | 0.010 |
| Sexual enjoyment | 16 | 13 | -1.20 | 0.04 | 39 | -0.43 | 0.14 | 33 | 0.19 | 0.49 |
| Future perspective | 13 | 122 | -0.56 | <0.01 | 135 | -0.46 | <0.01 | 144 | 0.01 | 0.95 |
| STSE | 1 - 4; 6 - 8 | 55 | -0.40 | <0.01 | 61 | 0.21 | 0.013 | 77 | -0.74 | <0.001 |
| Breast symptoms | 20 - 23 | 114 | -0.11 | 0.07 | 135 | 0.36 | 0.01 | 190 | -0.76 | <0.001 |
| Arm symptoms | 17 - 19 | 97 | 0.64 | <0.001 | 167 | 0.86 | <0.001 | 156 | -0.37 | 0.001 |
| Hair loss | Q5 | 6 | 0.22 | 0.738 | 16 | 0.12 | 0.808 | 24 | -0.33 | 0.149 |
aT1 → T2_R: comparison of baseline quality of life assessment and retrospective measure performed after surgery.
bT1 → T3_R: comparison of baseline quality of life assessment and retrospective measure performed three months later.
cT3 → T4_R: comparison of quality of life assessment at three months and retrospective measure performed three months later.
dQ5 was excluded because of the patients’ responses to this item at baseline: all patients chose either category 1 or 2 for this item at baseline, whereas all four categories were represented on retrospective measures.
eτ =0.364: patients significantly chose higher response categories at the retrospective measure of baseline HRQoL performed after surgery.
Figure 2Graph representing the correlation between QLQ-C30 scores and the first two principal components of Principal Component Analysis at each prospective measurement time (N = 192): at baseline (Panel A), just after surgery (Panel B), at three months (Panel C) and at six months (Panel D). The QLQ-C30 measures five functional scales (physical functioning (pf), role functioning (rf), emotional functioning (ef), cognitive functioning (cf), social functioning (sf)), global health status (GHS), financial difficulties (Fi) and eight symptom scales (fatigue (fa), nausea and vomiting (na), pain (pa), dyspnea (dy), insomnia (in), appetite loss (A), constipation (CO), diarrhea (Dia)).
Correlation between quality of life scores and the first two first axis of principal component analysis on prospective measures
| QLQ-C30 (N = 192) | | | | | | | | |
| GHS | -0.74 | 0.17 | -0.72 | -0.06 | -0.79 | -0.09 | -0.79 | 0.03 |
| Physical functioning | -0.76 | -0.33 | -0.76 | 0.01 | -0.79 | 0.11 | -0.81 | 0.03 |
| Role functioning | -0.85 | -0.22 | -0.81 | -0.05 | -0.85 | -0.05 | -0.87 | 0.01 |
| Emotional functioning | -0.46 | 0.71 | -0.56 | 0.33 | -0.68 | 0.31 | 0.73 | 0.23 |
| Cognitive functioning | -0.57 | 0.34 | -0.69 | 0.01 | -0.67 | 0.34 | -0.70 | 0.23 |
| Social functioning | -0.71 | -0.01 | -0.70 | 0.13 | -0.79 | -0.01 | -0.86 | 0.06 |
| Fatigue | 0.84 | 0.03 | 0.85 | -0.01 | 0.90 | 0.02 | 0.87 | 0.02 |
| Nausea and vomiting | 0.63 | 0.01 | 0.56 | 0.18 | 0.46 | 0.70 | 0.40 | 0.69 |
| Pain | 0.77 | 0.19 | 0.81 | 0.07 | 0.69 | -0.33 | 0.75 | -0.02 |
| Dyspnea | 0.66 | 0.35 | 0.55 | 0.22 | 0.62 | -0.14 | 0.67 | -0.09 |
| Insomnia | 0.41 | -0.63 | 0.54 | -0.38 | 0.63 | -0.15 | 0.63 | -0.23 |
| Appetite loss | 0.51 | -0.43 | 0.65 | -0.11 | 0.61 | 0.46 | 0.48 | 0.66 |
| Constipation | 0.36 | 0.12 | 0.25 | -0.42 | 0.44 | 0.37 | 0.42 | 0.25 |
| Diarrhea | 0.24 | 0.13 | 0.17 | 0.66 | 0.32 | 0.27 | 0.32 | 0.04 |
| Financial difficulties | 0.40 | 0.49 | 0.31 | 0.64 | 0.44 | -0.11 | 0.38 | -0.16 |
| QLQ-BR23 (N = 154) | | | | | ||||
| Body image | -0.70 | 0.47 | -0.64 | 0.45 | -0.79 | 0.07 | -0.79 | 0.25 |
| Sexual functioning | 0.30 | -0.44 | 0.24 | -0.52 | 0.31 | -0.51 | 0.41 | -0.41 |
| Future perspective | -0.31 | 0.46 | -0.53 | 0.52 | -0.76 | 0.25 | -0.73 | 0.30 |
| Systemic therapy side effects | 0.78 | -0.01 | 0.72 | 0.28 | 0.61 | -0.49 | 0.67 | -0.21 |
| Breast symptoms | 0.58 | 0.49 | 0.64 | 0.38 | 0.56 | 0.66 | 0.57 | 0.64 |
| Arm symptoms | 0.66 | 0.49 | 0.75 | 0.32 | 0.69 | 0.44 | 0.63 | 0.57 |
Figure 3Graph representing the correlation between QLQ-BR23 scores and the first two principal components of Principal Component Analysis at each prospective measurement time (N = 154): at baseline (Panel A), just after surgery (Panel B), at three months (Panel C) and at six months (Panel D). The QLQ-BR23 measures four functional scales (body image (BI), sexual functioning (SEXF), sexual enjoyment (SE), future perspective (FP)) and four symptom scales (systemic therapy side effects (STSE), breast symptoms (BS), arm symptoms (AS), upset by hair loss (HL)). SE and HL are excluded from these analyses.